肿瘤治疗相关骨髓抑制院外管理专家共识(2025版)  

Expert consensus on the out-of-hospital management of myelosuppression associated with oncological treatment(2025 edition)

作　　者：中国抗癌协会肿瘤临床化疗专业委员会 沈波[2] 史艳侠[3] China Anti-Cancer Association Tumor Clinical Chemotherapy Professional Committee;Shen Bo;Shi Yanxia(不详;Department of Medical Oncology,Jiangsu Cancer Hospital,Nanjing 210006,China;Department of Medical Oncology,Sun Yat-sen University Cancer Center,Guangzhou 510060,China)

机构地区：[1]不详 [2]江苏省肿瘤医院肿瘤内科,南京210006 [3]中山大学肿瘤防治中心肿瘤内科,广州510060

出　　处：《中华医学杂志》2025年第11期793-804,共12页National Medical Journal of China

基　　金：国家自然科学基金(82272863)。

摘　　要：骨髓抑制是肿瘤治疗中常见的血液学不良反应,主要包括中性粒细胞减少、血小板减少和贫血。因其临床表现具有一定的滞后性,完善的院外管理体系有助于临床医师更好地预防和管理肿瘤治疗相关骨髓抑制,保证抗肿瘤治疗的有效性和安全性。本共识围绕肿瘤治疗相关骨髓抑制的定义与分级、院外管理原则、管理流程以及管理方式等方面进行了详细的梳理和总结,制定了肿瘤治疗相关骨髓抑制风险分层评估表,并依据风险分层提出8条推荐意见,旨在为医务工作者提供肿瘤治疗相关骨髓抑制院外管理的参考方案。Myelosuppression is a common hematological side effect of oncological treatment,mainly including neutropenia,thrombocytopenia and anemia.Due to the delay in its clinical manifestation,a well-established out-of-hospital management system can help clinicians better prevent and manage the myelosuppression associated with oncology treatment and ensure the effectiveness and safety of antitumor therapy.This consensus focuses on a detailed compilation and summary of the definition and grading of myelosuppression associated with oncological treatment,the principles of out-of-hospital management,the management process and management methods,develops a risk stratification assessment table for oncology treatment-related myelosuppression,and puts forward 8 recommendations based on the risk stratification,which is aimed at providing medical workers with a reference plan for the out-of-hospital management of myelosuppression associated with oncological treatment.

关 键 词：肿瘤 中性粒细胞减少 血小板减少 贫血 院外管理 

分 类 号：R73[医药卫生—肿瘤]